Nine pharma trends for 2020Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for Share XNine pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/nine-pharma-trends-for-2020/
China’s Adagene raises $69m for cancer immunotherapiesChinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including Share XChina’s Adagene raises $69m for cancer immunotherapieshttps://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Geopolitical uncertainty grips digital health investorsGalen Growth Asia has released its Q3 2019 Asia Pac HealthTech, aka digital health, ecosystem key trends interim Share XGeopolitical uncertainty grips digital health investorshttps://pharmaphorum.com/views-analysis-digital/geopolitical-uncertainty-grips-digital-health-investors/
Amgen pays $2.7bn to harness BeiGene’s China marketing muscleFuelled by sweeping regulatory reforms and a massive ageing population, China is a key market for most big Share XAmgen pays $2.7bn to harness BeiGene’s China marketing musclehttps://pharmaphorum.com/news/amgen-pays-2-7bn-to-harness-beigenes-china-marketing-muscle/
OnQuality Pharma raises $15m for drug to treat VEGF side effectsOnQuality Pharmaceuticals has raised $15 million in first-round financing to fund development of a drug that treats side Share XOnQuality Pharma raises $15m for drug to treat VEGF side effectshttps://pharmaphorum.com/news/onquality-pharma-raises-15m-for-drug-to-treat-vegf-side-effects/
AZ gets China nod for Tagrisso in first-line lung cancerAstraZeneca has scored another approval for one of its new drugs in China, this time getting a green Share XAZ gets China nod for Tagrisso in first-line lung cancerhttps://pharmaphorum.com/news/az-gets-china-nod-for-tagrisso-in-first-line-lung-cancer/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
China in the fast laneBrett Gardiner and Boon Yap from Research Partnership discuss access opportunities for novel therapies in the world’s hottest Share XChina in the fast lanehttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/research-partnership-pharma-market-access-china/
